Rigel Pharmaceuticals, Inc (RIGL) Covered Calls

Rigel Pharmaceuticals, Inc covered calls Rigel Pharmaceuticals, Inc is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.

You can sell covered calls on Rigel Pharmaceuticals, Inc to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for RIGL (prices last updated Mon 4:16 PM ET):

Rigel Pharmaceuticals, Inc (RIGL) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.25 -0.12 2.25 2.28 2.3M -3.2 0.4B
Covered Calls For Rigel Pharmaceuticals, Inc (RIGL)
Expiration Strike Call Bid Net Debit Return
If Flat
Return If Flat
May 17 2.5 0.10 2.18 4.6% 64.6%
Jun 21 2.5 0.25 2.03 12.3% 73.6%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel Pharmaceuticals focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Its current product development programs include fostamatinib, an inhibitor for rheumatoid arthritis, R343, an inhibitor for asthma, R333 for the treatment of lupus of the skin and R348 for the treatment of keratoconjunctivitis sicca or chronic dry eye. Rigel Pharmaceuticals was founded by Donald G. Payan, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.